肾细胞癌的新辅助与辅助免疫治疗策略:优势、劣势与未来方向
本文为叙述性综述,批判性评估肾细胞癌围手术期辅助与新辅助免疫治疗的利弊。辅助帕博利珠单抗已成为高危复发患者术后新标准,KEYNOTE-564 3期试验显示无病生存和总生存获益;当前数据不支持临床试验外使用新辅助治疗。
要点
- 辅助帕博利珠单抗是肾切除术后高复发风险患者的新标准治疗,KEYNOTE-564 3期试验显示无病生存和总生存获益。
- 当前数据不支持临床试验外使用新辅助治疗。
- 新辅助与辅助免疫治疗均存在过度治疗和毒性风险,且缺乏生物标志物指导患者选择与治疗降阶。
核心结论
- 辅助免疫治疗是肾细胞癌的新标准治疗,新辅助与辅助策略各有潜在优势与劣势,新辅助免疫治疗的作用尚待明确。
- 鉴于围手术期免疫治疗有强有力的生物学依据,需要前瞻性临床试验确定临床疗效。
- 需要研究有助于患者选择和治疗降阶策略的生物标志物。
研究设计与样本
- 本文为协作性叙述性综述,检索并总结现有文献。
主要发现
- 辅助帕博利珠单抗在KEYNOTE-564 3期试验中显示无病生存和总生存获益。
- 当前数据不支持临床试验外使用新辅助治疗。
- 新辅助单药免疫检查点抑制剂对原发肿瘤活性有限,免疫联合方案可能活性更高。
- 新辅助与辅助策略均存在过度治疗及手术治愈患者的相关毒性风险。
- 肾细胞癌缺乏辅助患者选择和治疗降阶的生物标志物。
关键数值与推荐
- 辅助帕博利珠单抗为肾切除术后高复发风险患者的新标准治疗,依据为KEYNOTE-564 3期试验的无病生存和总生存获益。
- 当前数据不支持临床试验外使用新辅助治疗。
临床怎么用
- 辅助帕博利珠单抗是肾切除术后高复发风险患者的新标准治疗。
- 新辅助免疫治疗应在临床试验中进一步研究。
- 未来试验应关注患者选择,以避免手术治愈患者承受毒性。
局限性
- 肾细胞癌缺乏辅助患者选择和治疗降阶的生物标志物。
- 尚无比较新辅助或围手术期免疫治疗与辅助免疫治疗的随机试验结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Immune-oncology strategies are revolutionising the perioperative treatment in several tumour types. The perioperative setting of renal cell carcinoma (RCC) is an evolving field, and the advent of immunotherapy is producing significant advances. OBJECTIVE: To critically review the potential pros and cons of adjuvant and neoadjuvant immune-based therapeutic strategies in RCC, and to provide insights for future research in this field. EVIDENCE ACQUISITION: We performed a collaborative narrative review of the existing literature. EVIDENCE SYNTHESIS: Adjuvant immunotherapy with pembrolizumab is a new standard of care for patients at a higher risk of recurrence after nephrectomy, demonstrating a disease-free survival and overall survival benefit in the phase 3 KEYNOTE-564 trial. Current data do not support neoadjuvant therapy use outside clinical trials. While both adjuvant and neoadjuvant immune-based approaches are driven by robust biological rationale, neoadjuvant immunotherapy may enable a stronger and more durable antitumour immune response. If neoadjuvant single-agent immune checkpoint inhibitors demonstrated limited activity on the primary tumour, immune-based combinations may show increased activity. Overtreatment and a risk of relevant toxicity for patients who are cured by surgery alone are common concerns for both neoadjuvant and adjuvant strategies. Biomarkers helping patient selection and treatment deintensification are lacking in RCC. No results from randomised trials comparing neoadjuvant or perioperative immune-based therapy with adjuvant immunotherapy are available. CONCLUSIONS: Adjuvant immunotherapy is a new standard of care in RCC. Both neoadjuvant and adjuvant immunotherapy strategies have potential advantages and disadvantages. Optimising perioperative treatment strategies is nuanced, with the role of neoadjuvant immune-based therapies yet to be defined. Given strong biological rationale for a pre/perioperative approach, there is a need for prospective clinical trials to determine clinical efficacy. Research investigating biomarkers aiding patient selection and treatment deintensification strategies is needed. PATIENT SUMMARY: Immunotherapy is transforming the treatment of kidney cancer. In this review, we looked at the studies investigating immunotherapy strategies before and/or after surgery for patients with kidney cancer to assess potential pros and cons. We concluded that both neoadjuvant and adjuvant immunotherapy strategies may have potential advantages and disadvantages. While immunotherapy administered after surgery is already a standard of care, immunotherapy before surgery should be better investigated in future studies. Future trials should also focus on the selection of patients in order to spare toxicity for patients who will be cured by surgery alone.
引用
- Marandino L, Campi R, Amparore D, et al. Neoadjuvant and Adjuvant Immune-based Approach for Renal Cell Carcinoma: Pros, Cons, and Future Directions. Eur Urol Oncol. 2024. PMID: 39327187. doi:10.1016/j.euo.2024.09.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。